Abstract:OBJECTIVE:To evaluate the safety of enterovirus type 71 (EV71) inactivated vaccine (human diploid derived) for infection prevention in an animal model by investigating the immune responses and related patho-inflammatory reactions.METHODS:In the neonatal monkey model for EV71 vaccine protection, vaccinated group (n = 4) and unvaccinated group (n = 4) were attacked with live virus at the same time, the parameters of clinical observations, antibodies and inflammatory factors in peripheral blood and cerebrospinal fluid (CSF) were detected. And the pathological changes in major organs were used to determine the patho-inflammatory reactions during the immune responses elicited by vaccination.RESULTS:The neutralizing antibodies of vaccine group reach to 1:32. There was no obvious changes of inflammatory factors in peripheral blood and CSF of monkeys challenged or unchallenged by live virus. In peripheral blood of unvaccinated group, the level of basophilic granulocyte higher 4 - 5 times than normal level and the interferon-γ (IFN-γ) showed obvious increase. Live virus infected after 7 days, the interleukin-6 (IL-6) and IFN-γ in peripheral blood of unvaccinated group (18.5, 12.7 pg/ml) were higher than vaccinated group (10.2, 7.6 pg/ml). Furthermore, the IL-6 in CSF (102.0 pg/ml) had 4 - 5 times increased than vaccinated group (12.4 pg/ml) at 7 days after virus exposure. Meanwhile, the pathological analysis revealed that no obvious changes were detected in CNS and other organs of vaccinated monkeys challenged with live virus. However, the pathological damages induced by virus infection could be determined in the unvaccinated control monkeys, including neuronal damage, massive cellular infiltration associated with pulmonary edema/hemorrhage and pulmonary/bronchial damage due to an infiltration of inflammatory cells.CONCLUSION:Capable of inducing an immune response, the EV71 inactivated vaccine offers protection to neonatal rhesus monkeys against the attacks of live virus. Based on the results of no patho-inflammatory reaction and pathological damage after viral infection in vaccinated animals, the excellent safety of this vaccine may be confirmed in neonatal monkey.

Immunization response of enterovirus 71 whole virus inactivation antigen combined with PA adjuvant by nasal mucosa in mice

Screening of Antigenic Epitopes of Inactivated Enterovirus 71 Vaccine Inducing Cellular Immunity in Mice

Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice

Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71

Immunological Effect of Different Immunization Schedules on Enterovirus 71

Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice

Evaluation of Immune Responses and Related Patho-Inflammatory Reactions of a Candidate Inactivated EV71 Vaccine in Neonatal Monkeys

Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine

Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally

[Preparation of monoclonal antibody against enterovirus 71 capsid protein VP1].

Preparation and characterization of enterovirus 71 VP1 monoclonal antibody

Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection

The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals

In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody Against Lethal Enterovirus 71 Infection in a Mouse Model.

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine

Immunoprotection of Inactivated EV71 Vaccine Against Enterovirus in Neonatal Rhesus Monkey

A Polysaccharide Purified From Ganoderma lucidum Acts as a Potent Mucosal Adjuvant That Promotes Protective Immunity Against the Lethal Challenge With Enterovirus A71

[Preparation of monoclonal antibodies against enterovirus type 71 with an epitope-incorporated adenovirus type 3 vector].

A safety study of inactivated Enterovirus 71 vaccine

Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses

Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.